The robotic surgical procedures market size was valued at USD 14.57 billion in 2025 and is estimated to grow from USD 17.04 billion in 2026 to reach USD 37.32 billion by 2031, at a CAGR of 16.97% during the forecast period (2026-2031). This report is Segmented by Application (Urology, General Surgery, and More), Procedure Type (Minimally Invasive Laparoscopic, and More), End User (Large Hospital Systems, Standalone and Private Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Orthopedics is the fastest-growing segment, with a forecast CAGR of 17.90% through 2031. Recent advancements have reduced system footprints, image dependency, and setup challenges, enabling orthopedic robots to move into outpatient settings. Stryker’s Mako RPS and Smith+Nephew’s CORI XT exemplify this shift. General surgery and gynecology are also expanding, with OTTAVA’s FDA submission in January 2026 and positive gastric bypass study results signaling broader platform applications. Neurosurgery and spine remain smaller segments, but Medtronic’s Stealth AXiS demonstrates how shared platforms can enhance hospitals' capital efficiency.
Europe held the second-largest share in the robotic surgical procedures market. The region benefits from strong clinical research, universal healthcare systems, and a significant manufacturing presence. However, reimbursement remains less consistent compared to North America, exposing hospitals to higher economic risks when robotic benefits are not fully covered under existing payment structures. Despite this, Europe is advancing through selective platform adoption, particularly in orthopedic and minimally invasive applications, which support long-term utilization. Success in Europe under tighter budget constraints strengthens vendors' prospects for broader global adoption.
Asia-Pacific is projected to witness the fastest growth in the robotic surgical procedures market, with a CAGR of 17.45% through 2031. The region is transitioning from import reliance to stronger domestic competition, especially in China. Da Vinci procedures in Southeast Asia grew by 24% in 2025, reflecting increased utilization even in markets with smaller installed bases compared to North America and Europe. China's domestic surgical robot market is gaining traction, potentially reshaping pricing and platform access. India and South Korea contribute to regional growth through rising chronic disease burdens and private hospital investments, while the Middle East, Africa, and South America remain in early stages, focusing on medical tourism, hospital modernization, and selective platform adoption.
Global Robotic Surgical Procedures Market Trends and Insights
Expanded Clinical Validation Beyond Urology
The robotic surgical procedures market is transitioning from its reliance on urology to broader adoption across multiple specialties. In 2026, enhanced guidelines for Aquablation increased confidence in robotic treatments for benign prostatic hyperplasia, driving its use in urology. General surgery and gynecology are also gaining traction, with Johnson & Johnson's FORTE study meeting safety and performance benchmarks in a 30-patient gastric bypass cohort. Stable robotic performance in complex bariatric cases is expected to encourage payers and providers to extend adoption to related procedures, expanding the market's potential.AI-Enabled Surgical Planning and Workflow Standardization
Artificial intelligence is transforming the robotic surgical procedures market from hardware-driven purchases to workflow-focused models. Medtronic’s Stealth AXiS system, cleared by the FDA in February 2026 and CE Mark in April 2026, integrates planning, navigation, and robotic execution into a single platform. Moon Surgical’s Maestro Software Version 2.7, launched in June 2026, introduced automated operating room setup, navigation, and post-procedure documentation. These advancements simplify operations, making robotic systems more appealing to facilities previously deterred by staffing complexities.High Capital and Recurring Per-Procedure Cost Burden
Robotic surgical procedures grapple with significant cost hurdles, hindering their uptake beyond major medical centers. The financial strain extends beyond just acquiring the robotic system; costs for instruments, disposables, and upgrades play a pivotal role in the economics of each procedure. This challenge intensifies when insurers don't offer premium reimbursements for robotic surgeries compared to their laparoscopic counterparts. Consequently, medical providers are left to advocate for robotic adoption based on efficiency and patient outcomes rather than direct financial incentives. A case in point is Smith+Nephew’s CORI XT platform, which, while expanding capabilities to shoulder surgeries, introduces a substantial capital challenge for facilities still ramping up their orthopedic volumes. Consequently, adoption of robotic procedures is largely confined to tertiary hospitals, specialized clinics, and a select few busy outpatient centers.Other drivers and restraints analyzed in the detailed report include:
- Ambulatory Surgical Center Platform Fit and Throughput
- Value-Based Procurement Tied to Measurable Outcomes
- OR Integration Complexity and Staff Training Dependencies
Segment Analysis
In 2025, urology accounted for 31.76% of the robotic surgical procedures market, maintaining its position as the leading application segment. This dominance stems from the widespread adoption of robotic prostatectomies and faster clinical acceptance compared to other specialties. The growing guideline support for Aquablation in 2026 further strengthened robotic urologic care's role in the market. Hospitals find this segment appealing as they can increase procedure volumes without creating new clinical categories.Orthopedics is the fastest-growing segment, with a forecast CAGR of 17.90% through 2031. Recent advancements have reduced system footprints, image dependency, and setup challenges, enabling orthopedic robots to move into outpatient settings. Stryker’s Mako RPS and Smith+Nephew’s CORI XT exemplify this shift. General surgery and gynecology are also expanding, with OTTAVA’s FDA submission in January 2026 and positive gastric bypass study results signaling broader platform applications. Neurosurgery and spine remain smaller segments, but Medtronic’s Stealth AXiS demonstrates how shared platforms can enhance hospitals' capital efficiency.
Complete Report Scope:
- By Application
- Urology
- General Surgery
- Gynecology
- Orthopedics
- Cardiothoracic Surgery
- Neurosurgery
- Ear, Nose, and Throat Surgery
- Bariatric and Metabolic Surgery
- Other Applications
- By Procedure Type
- Minimally Invasive Laparoscopic Robotic-Assisted Procedures
- Percutaneous and Catheter-Based Robotic Procedures
- Endoscopic Robotic Procedures
- Open-Assisted Hybrid Procedures
- Other Procedure Types
- By End User
- Large Hospital Systems
- Standalone and Private Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
In 2025, North America accounted for 43.55% of the robotic surgical procedures market, maintaining its position as the largest regional contributor. The region benefits from strong reimbursement frameworks in robotic urology, higher utilization rates per installed system, and a well-established training base for surgeons and care teams. Intuitive reported a 15% increase in US da Vinci procedures in 2025, alongside a 31% rise in after-hours procedure utilization in Q1 2026. This indicates that market growth is driven by better utilization of existing systems rather than solely by new installations. While Canada and Mexico are progressing, the US continues to lead the region in terms of volume, reimbursement, and platform approvals.Europe held the second-largest share in the robotic surgical procedures market. The region benefits from strong clinical research, universal healthcare systems, and a significant manufacturing presence. However, reimbursement remains less consistent compared to North America, exposing hospitals to higher economic risks when robotic benefits are not fully covered under existing payment structures. Despite this, Europe is advancing through selective platform adoption, particularly in orthopedic and minimally invasive applications, which support long-term utilization. Success in Europe under tighter budget constraints strengthens vendors' prospects for broader global adoption.
Asia-Pacific is projected to witness the fastest growth in the robotic surgical procedures market, with a CAGR of 17.45% through 2031. The region is transitioning from import reliance to stronger domestic competition, especially in China. Da Vinci procedures in Southeast Asia grew by 24% in 2025, reflecting increased utilization even in markets with smaller installed bases compared to North America and Europe. China's domestic surgical robot market is gaining traction, potentially reshaping pricing and platform access. India and South Korea contribute to regional growth through rising chronic disease burdens and private hospital investments, while the Middle East, Africa, and South America remain in early stages, focusing on medical tourism, hospital modernization, and selective platform adoption.
List of Companies Covered in this Report:
- Asensus Surgical, Inc.
- Brain Lab
- CMR Surgical Ltd.
- Curexo, Inc.
- Distalmotion SA
- Globus Medical
- Intuitive Surgical, Inc.
- Johnson & Johnson
- Medical Microinstruments S.p.A.
- Medtronic
- Monteris Medical Corporation
- Neocis Inc.
- PROCEPT BioRobotics Corporation
- Renishaw plc
- Siemens Healthineers
- Smiths Group
- SS Innovations International, Inc.
- Stryker
- THINK Surgical, Inc.
- Zimmer Biomet
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Asensus Surgical, Inc.
- Brainlab AG
- CMR Surgical Ltd.
- Curexo, Inc.
- Distalmotion SA
- Globus Medical, Inc.
- Intuitive Surgical, Inc.
- Johnson & Johnson
- Medical Microinstruments S.p.A.
- Medtronic plc
- Monteris Medical Corporation
- Neocis Inc.
- PROCEPT BioRobotics Corporation
- Renishaw plc
- Siemens Healthineers AG
- Smith & Nephew plc
- SS Innovations International, Inc.
- Stryker Corporation
- THINK Surgical, Inc.
- Zimmer Biomet Holdings, Inc.
